News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
456,046 Results
Type
Article (38648)
Company Profile (142)
Press Release (417256)
Multimedia
Podcasts (32)
Webinars (11)
Section
Business (138059)
Career Advice (1410)
Deals (22618)
Drug Delivery (82)
Drug Development (49106)
Employer Resources (152)
FDA (8010)
Job Trends (9884)
News (218699)
Policy (16632)
Tag
Academia (2115)
Academic (2)
Accelerated approval (4)
Adcomms (16)
Allergies (47)
Alliances (33045)
ALS (72)
Alzheimer's disease (1038)
Antibody-drug conjugate (ADC) (86)
Approvals (8035)
Artificial intelligence (201)
Autoimmune disease (14)
Automation (10)
Bankruptcy (163)
Best Places to Work (7786)
BIOSECURE Act (12)
Biosimilars (65)
Biotechnology (94)
Bladder cancer (51)
Brain cancer (18)
Breast cancer (187)
Cancer (1456)
Cardiovascular disease (130)
Career advice (1197)
Career pathing (33)
CAR-T (115)
Cell therapy (312)
Cervical cancer (11)
Clinical research (38793)
Collaboration (620)
Compensation (317)
Complete response letters (11)
COVID-19 (1692)
CRISPR (39)
C-suite (232)
Cystic fibrosis (67)
Data (1629)
Decentralized trials (1)
Denatured (22)
Depression (32)
Diabetes (171)
Diagnostics (4425)
Digital health (9)
Diversity (7)
Diversity, equity & inclusion (41)
Drug discovery (90)
Drug pricing (48)
Drug shortages (9)
Duchenne muscular dystrophy (72)
Earnings (52404)
Editorial (23)
Employer branding (24)
Employer resources (133)
Events (73851)
Executive appointments (625)
FDA (8825)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (6)
Funding (583)
Gene editing (79)
Generative AI (19)
Gene therapy (210)
GLP-1 (477)
Government (2192)
Grass and pollen (1)
Guidances (108)
Healthcare (11249)
Huntington's disease (18)
IgA nephropathy (19)
Immunology and inflammation (56)
Indications (17)
Infectious disease (1784)
Inflammatory bowel disease (111)
Inflation Reduction Act (7)
Influenza (30)
Intellectual property (53)
Interviews (205)
IPO (10855)
IRA (18)
Job creations (2425)
Job search strategy (1067)
Kidney cancer (9)
Labor market (40)
Layoffs (287)
Leadership (16)
Legal (3817)
Liver cancer (48)
Lung cancer (203)
Lymphoma (100)
Machine learning (6)
Management (48)
Manufacturing (202)
MASH (47)
Medical device (7129)
Medtech (7134)
Mergers & acquisitions (12200)
Metabolic disorders (438)
Multiple sclerosis (62)
NASH (14)
Neurodegenerative disease (59)
Neuropsychiatric disorders (10)
Neuroscience (1437)
NextGen: Class of 2025 (3955)
Non-profit (2882)
Now hiring (40)
Obesity (227)
Opinion (149)
Ovarian cancer (45)
Pain (52)
Pancreatic cancer (50)
Parkinson's disease (106)
Partnered (17)
Patents (117)
Patient recruitment (62)
Peanut (23)
People (46164)
Pharmaceutical (36)
Pharmacy benefit managers (3)
Phase I (11849)
Phase II (16823)
Phase III (13550)
Pipeline (994)
Policy (73)
Postmarket research (1498)
Preclinical (6372)
Press Release (72)
Prostate cancer (70)
Psychedelics (21)
Radiopharmaceuticals (176)
Rare diseases (236)
Real estate (4141)
Recruiting (58)
Regulatory (11840)
Reports (49)
Research institute (1973)
Resumes & cover letters (216)
Rett syndrome (4)
RNA editing (3)
RSV (29)
Schizophrenia (57)
Series A (109)
Series B (66)
Service/supplier (8)
Sickle cell disease (41)
Special edition (10)
Spinal muscular atrophy (106)
Sponsored (20)
Startups (2852)
State (1)
Stomach cancer (8)
Supply chain (39)
Tariffs (21)
The Weekly (10)
Vaccines (365)
Venture capitalists (34)
Weight loss (128)
Women's health (17)
Worklife (18)
Date
Last 7 days (662)
Last 30 days (2056)
Last 365 days (21885)
2025 (7915)
2024 (24473)
2023 (28277)
2022 (35762)
2021 (38986)
2020 (36130)
2019 (29246)
2018 (21936)
2017 (21867)
2016 (21105)
2015 (25617)
2014 (20599)
2013 (17438)
2012 (16796)
2011 (17383)
2010 (16650)
Location
Africa (576)
Alabama (29)
Alaska (5)
Arizona (131)
Arkansas (5)
Asia (25557)
Australia (4468)
California (4346)
Canada (1488)
China (277)
Colorado (186)
Connecticut (195)
Delaware (119)
Europe (61156)
Florida (583)
Georgia (115)
Hawaii (1)
Idaho (36)
Illinois (290)
India (20)
Indiana (236)
Iowa (8)
Japan (140)
Kansas (52)
Kentucky (16)
Louisiana (11)
Maine (46)
Maryland (503)
Massachusetts (3400)
Michigan (197)
Minnesota (226)
Mississippi (1)
Missouri (62)
Montana (19)
Nebraska (19)
Nevada (52)
New Hampshire (33)
New Jersey (1262)
New Mexico (27)
New York (1283)
North Carolina (737)
North Dakota (8)
Northern California (1981)
Ohio (149)
Oklahoma (8)
Oregon (33)
Pennsylvania (864)
Puerto Rico (6)
Rhode Island (26)
South America (745)
South Carolina (16)
Southern California (1596)
Tennessee (68)
Texas (585)
United States (16121)
Utah (146)
Virginia (86)
Washington D.C. (37)
Washington State (357)
West Virginia (2)
Wisconsin (54)
456,046 Results for "sanmina sci corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Winka Dubbeldam Appointed Director and CEO of SCI-Arc
April 28, 2025
·
3 min read
Business
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments.
May 16, 2024
·
7 min read
Press Releases
CEL-SCI Announces Closing of $2.5 Million Offering
March 18, 2025
·
4 min read
Press Releases
CEL-SCI Announces Pricing of $2.5 Million Offering
March 18, 2025
·
4 min read
Business
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
CEL-SCI Corporation reported financial results for the quarter ended December 31, 2023, as well as key recent clinical and corporate developments.
February 15, 2024
·
7 min read
Business
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
CEL-SCI Corporation announced Dr. Giovanni Selvaggi, an oncology key opinion leader instrumental in successfully bringing several drugs to market has joined CEL-SCI as a Clinical Advisor.
June 6, 2024
·
7 min read
Press Releases
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
February 20, 2025
·
7 min read
Press Releases
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
April 23, 2025
·
5 min read
Business
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
CEL-SCI Corporation announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy.
April 23, 2024
·
4 min read
Press Releases
CEL-SCI Announces Closing of $5 Million Offering
January 1, 2025
·
4 min read
1 of 45,605
Next
